# Pathophysiology of High Output Arteriovenous Fistula with Heart Failure: A Systematic Review and Meta-analysis

ANUSUYA PREMJITHLAL BHASKARAN<sup>1</sup>, INDIA PREMJITHLAL BHASKARAN<sup>2</sup>, PREMJITHLAL BHASKARAN<sup>3</sup>

CC) BY-NC-ND

# **ABSTRACT**

Others Section

**Introduction:** Arteriovenous Fistula (AVF) is extensively used as vascular access for haemodialysis patients. It induces a high output state, which is associated with cardiac remodeling. With High Output Heart Failure (HOHF), the AVF occupies a low pressure; reduced vascular resistance and increased venous return. The High Output Arteriovenous Fistula with Heart Failure (HOHF-AVF) patients often undergo a comprehensive assessment of type of underlying diseases, the degree of vasodilatation along with laboratory investigations and cardiac imaging. Hence identification of the pathophysiological determinants of HOHF-AVF is intriguing.

Aim: To identify the pathophysiological determinants of HOHF-AVF.

**Materials and Methods:** This systematic review was conducted from May 2021 to December 2021 at the Department of Cardiovascular Surgery, Imperial College, United Kingdom. Randomised Controlled Trials (RCTs), cohort, case-control, cross-sectional and descriptive studies, conducted on adult patients who underwent AVF creation or ligation and addressed the pathophysiological determinants of HOHF-AVF were included. Studies conducted among Paediatric cases, case reports, and case series were excluded. Medline (PubMed), EMBASE, ProQuest, and the Cochrane database were searched, by utilising the key words {[["HOHF" OR "High output heart failure") AND ("AVF" OR "Arteriovenous fistula")] AND ("LV parameters" OR "Structural Characteristics" OR "Echocardiographic indices)}. The searches were restricted from January 2000 to October 2021 with studies published in the English language. All the included studies were subjected to critical appraisal using the "Cochrane risk of bias assessment tool" for RCTs, and the "Joanna Briggs Institute (JBI) checklist" for cohort, case-control, cross-sectional and descriptive studies. For meta-analysis Mantel-Haenszel Odds Ratio (M.H. O.R.) with its 95% Confidence Interval (C.I), Mean Difference (M.D) with its 95% C.I were computed. The Review Manager Software (Rev Man 5, Cochrane collabouration, Oxford, England) was used for data analytics.

**Results:** Overall, 115 citations were identified from the initial search, of which 29 studies were retrieved. Later, 14 studies were excluded. Of the remaining 15 studies, 12 were subjected to meta-analysis. There was a change in Left Ventricular (LV) end diastolic diameter (M.D=2.0; p<0.001; 95% C.I=1.13 to 2.86), and cardiac index (M.D=0.63; p<0.001, 95% C.I=0.46 to 0.79) from baseline to atleast three months of postsurgery among HOHF-AVF patients. According to the AVF flow, there was a change in LV systolic diameter (M.D=-18.90; p<0.01; 95% C.I=-22.84 to-14.96), cardiac index (M.D=0.50; p=0.007; 95% C.I=0.14 to 0.86) and tricuspid annular plane systolic excursion (M.D=3.90; p=0.03; 95% C.I=0.30 to 7.50).

**Conclusion:** Left ventricular end diastolic diameter and cardiac index were found to be the major determinants for a HOHF-AVF. The left ventricular mass index, ejection fraction, posterior wall thickness, interventricular septum were not associated with HOHF-AVF. Left ventricular systolic diameter, cardiac index and tricuspid annular plane systolic excursion were the determinants of AVF flow.

#### Keywords: Cardiac index, Cardiac remodeling, Echocardiographic indices, Ejection fraction, Structural characteristics

### INTRODUCTION

The Arteriovenous Fistula (AVF) can cause or exacerbate heart failure, ventricular hypertrophy or dysfunction, pulmonary hypertension, and Coronary Artery Disease (CAD). Chances of having pre-existing adverse cardiac events are higher among haemodialysis patients [1]. In order to maintain vascular perfusion, the increase in cardiac output and blood flow through an AVF (one to two litres per minute) must be atleast equal [2]. Dyspnoea, decreased exercise tolerance, peripheral oedema, and fatigue were common among HOHF patients [2,3]. Thus, a comparison of the pathophysiological characteristics of persistence versus systematic closure of AVF is important to evaluate the cardiac impact of a functioning AVF and echocardiographic abnormalities.

The symptomatic fistula with HOHF should be subjected to either reconstruction or ligation. The AVF flow (800 mL/min) or AV graft (1200 mL/min) were the diagnostic marker for HF resulted from the high flow vascular access [4]. However, vascular access closure among kidney allograft recipients was limited. The successful transplantation can be followed a safe closure of an aneurysmatic fistula. It can lead by

the occurrence of steal syndrome, cosmetic defects, inflammation, oedema, and the risk of HF [5]. The flow restriction procedure of AVF involves the creation of a surgical stenosis within the venous access site to curtail the radius. It involves the ligation of fistula and then attaching it distally with the jump grafts [2].

The requirement for fistula repair or the creation of a new AVF is a challenge, especially if there is a contraindication for high flow graft or when HF develops along with allograft nephropathy. Fistula ligation among the stable kidney allograft recipient may not yield any beneficial effect on cardiac structure and function in patients without the history of HF. High cardiac output maintains the ejection fraction and hence the surgical closure of an AVF in a patient with New York Heart Association class IV heart failure may result in adverse cardiac events [6,7].

In order to permit maturation, it is recommended to construct an AVF atleast six months prior to dialysis; and a graft can be used after three to six weeks [8]. Creation of a temporary vascular access should be preferred as the last option for first time access in HOHF-AVF patients [8]. After AVF creation, the chances of increase in cardiac output are higher due to the reduction in peripheral vascular resistance and rise in right ventricular preload. In patients on haemodialysis, conversion from AVF to catheter was followed, but use of the catheter as mode of vascular access carries high-risk of infection [9]. The detrimental effects of high flow AVF are the predictors of mortality, morbidity and adverse cardiac events. Thus, the surgical blood flow reduction is recommended as an elective to reduce the effect of a high flow on the heart, and it enhances the survival rate of a functioning AVF [9]. The creation or persistence of AVF followed by its closure resulted from HF, limb swelling, cosmetic complications, fatigue, and palpitations may result the AVF to progress the hypertrophy and high cardiac output [2,10]. Thus, an identification of pathophysiological determinants of HOHF-AVF is important to evaluate the cardiac impact of a functioning AVF and echocardiographic abnormalities.

This systematic review and meta-analysis was conducted to identify the pathophysiological determinants of HOHF-AVF.

# **MATERIALS AND METHODS**

This systematic review was conducted from May 2021 to December 2021 including the English literature from January 2000 to October 2021 at Department of Cardiovascular Surgery, Imperial College, London, United Kingdom.

**Inclusion criteria:** Randomised Controlled Trials (RCTs), cohort, case-control, cross-sectional, and descriptive studies, which made an attempt to address the pathophysiological determinants of HOHF-AVF were the inclusion criteria. The studies conducted on adult patients who underwent AVF creation or ligation irrespective of study setting and regions were included in the study.

**Exclusion criteria:** Studies conducted among paediatrics, case reports, and case series were excluded. If the outcome measure (pathophysiological determinants of HOHF-AVF) was not reported or was impossible to extract or calculate from the available results, then such studies were excluded from the study.

Medline (PubMed), EMBASE, ProQuest, and the Cochrane database were searched, by utilising a combination of the relevant Medical Subject Heading (MeSH) terms and the key words {[("HOHF" OR "High output heart failure") AND ("AVF" OR "Arteriovenous fistula")] AND ("LV parameters" OR "Structural Characteristics" OR "Echocardiographic indices)}. In the Cochrane database the search was limited by the term "clinical trial". The searches were restricted from January 2000 to October 2021 with studies published in the English language. Citations were screened at the title or abstract level and retrieved as a full report if they were clinical studies, addressed structural or echocardiographic characteristics of HOHF-AVF. PRISMA guidelines were followed in this systematic review.

Search strategy: Screening criteria in preliminary search were the pathophysiological determinants associated with HOHF-AVF. In the second phase full manuscripts of all the studies qualified the screening criteria, were obtained. Selection criteria were applied to each of these studies and valid studies were subjected for final data extraction.

**Methods used to collect the data:** The keywords {[("HOHF" OR "High output heart failure") AND ("AVF" OR "Arteriovenous fistula")] AND ("LV parameters" OR "Structural Characteristics" OR "Echocardiographic indices)} were entered into different database and year-wise search was conducted. Titles or abstracts were screened for the content and full manuscripts of the studies were obtained. All the downloaded articles were studied and subjected for eligibility criteria and a list of selected studies was obtained. They were further subjected for inclusion and relevant data were extracted.

Quality assessment: All the included studies for meta-analysis were subjected to methodological quality appraisal using the "Cochrane risk of bias assessment tool for RCTs", and the "Joanna Briggs Institute (JBI) checklist for case-control, cross-sectional, cohort and descriptive studies" [11,12]. For each item the response was recorded as "yes" or "no" and a credit point of "one" was assigned for "yes" and "zero" for "no".


**Data analysis:** For meta-analysis Mantel-Haenszel Odds Ratio (M.H. O.R.), mean difference (M.D), and 95% Confidence Interval (C.I) were computed by using the fixed effect model. The Chi-square and I<sup>2</sup> statistic were used to test heterogeneity [13]. The Review Manager Software (Rev Man 5, Cochrane collabouration, Oxford, England) was used for data analytics [14].

[Table/Fig-1] shows the PRISMA flow diagram. Total counts of all points for appraisal were obtained and higher counts indicate well appraisal [Table/Fig-2].

# RESULTS

studies)

Overall, 115 citations were identified from the initial search, of which 29 studies were retrieved. Later, 14 studies were excluded. Of the remaining 15 studies [15-29], 12 were subjected to meta-analysis in the second phase [15-26] [Table/Fig-2].



Author	Year of publication	Design	Sample size	Appraisal score**,#
Van Duijnhoven EC et al., [15]	2001	Cohort	20	8/12
Unger P et al., [16]	2002	Cohort	23	7/12
Sheashaa H et al., [17]	2004	Cohort	51	9/12
Unger P et al., [18]	2004	Cohort	25	8/12
Cridlig J et al., [19]	2008	RCT	76	5/7
Unger P et al., [20]	2009	Cohort	16	9/12
Gorgulu N et al., [21]	2011	Cohort	109	8/12
Głowiński J et al., [22]	2012	Cohort	18	8/12
Soleimani MJ et al., [23]	2012	Cohort	40	7/12
Dundon BK et al., [24]	2014	RCT	18	4/7
Papasotiriou M et al., [25]	2019	Cohort	99	8/12
Rao NN et al., [26]	2019	Cohort	54	8/12
Malik J et al., [27]*	2021	Cohort	26	7/12
Saleh MA et al., [28]*	2018	Descriptive	100	7/10
Salehi T et al., [29]*	2021	Descriptive	45	8/10
[Table/Fig-2]: Critical appraisa *:Excluded from meta-analysis **Cochrane risk of bias assessment t "Joanna Briggs Institute (JBI) checklis	ool (RCTs)		tional and de	scriptive

The studies selected for meta-analysis contributed a sample size 549. It included 292 (53.19%) closed AVF cases and 257 (46.81%) with persistent AVF (failure of complete healing of the AVF for more than six months followed by the surgery). Three studies had patients with closed AVF (n=54) and there was no comparison (persistent AVF) group [15,20,24]. Mean age of the study population of the closed AVF group was 46.61±11.17 years and in the persistent AVF group it was 46.14±9.21. Thus, age was homogeneous (M.D=-0.53; p=0.57; 95% C.I=-2.35 to 1.30) between the two groups of AVF [Table/Fig-3] [16-19,21-23,25,26].

	Closed A	VF	Pers	istent A	VF		Mean Difference	Mean Diffe	erence
Study or Subgroup	Mean SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed,	95% CI
Unger P et al., [16]	46 ± 13	17	40	± 6	6	5.5%	6.00 [-1.83, 13.83]	-	-
Sheashaa H et al., [17]	28.6 ± 8.5	17	25.6	± 7	34	15.3%	3.00 [-1.68, 7.68]	+	
Unger P et al., [18]	48 ± 11	17	49	± 6	8	7.5%	-1.00 [-7.68, 5.68]	+	
Cridlig J et al., [19]	49.07±10.4	38	49.5	± 8.1	38	19.0%	-0.43 [-4.62, 3.76]	+	
Gorgulu N et al., [21]	37 ± 11	49	39	± 12	60	17.8%	-2.00 [-6.32, 2.32]	+	
Głowiński J et al., [22]	49 ± 11	9	54	± 10	9	3.5%	-5.00 [-14.71, 4.71]	-+	
Soleimani MJ et al., [23]	39.2±12.4	17	49.1	± 11.8	23	5.8%	-9.90 [-17.52, -2.28]		
Papasotiriou M et al., [25]	55.3±11.3	47	55.8	±11.8	52	16.1%	-0.50 [-5.05, 4.05]	+	
Rao NN et al., [26]	60.2±11.9	27	59.9	± 10.2	27	9.6%	0.30 [-5.61, 6.21]	+	
Total (95% CI)		238			257	100.0%	-0.53 [-2.35, 1.30]		
Heterogeneity: Chi <sup>2</sup> = 12.0	3, df = 8 (p = 0	0.15); P	= 34%					-100 -50 0	50 100
Test for overall effect: Z =	0.57 (p=0.57	)						-100 -50 0 Closed AVF	Persistent AVF

The majority of the study population were males 145 (60.92%) in the closed AVF group and 171 (66.53%) in persistent AVF). Gender was not associated (M.H. O.R=0.84; p=0.35; 95% C.I=0.57 to 1.22) with the AVFs [Table/Fig-4].

	Closed	AVF	Persisten	t AVF		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Unger P et al., [16]	8	17	4	6	5.3%	0.44 [0.06, 3.11]	
Sheashaa H et al., [17]	13	17	27	34	7.2%	0.84 [0.21, 3.40]	
Unger P et al., [18]	12	17	3	8	2.0%	4.00 [0.68, 23.51]	+
Cridlig J et al., [19]	25	38	25	38	14.5%	1.00 [0.39, 2.58]	-+-
Gorgulu N et al., [21]	28	49	36	60	23.5%	0.89 [0.41, 1.91]	
Głowiński J et al., [22]	3	9	3	9	3.4%	1.00 [0.14, 7.10]	
Soleimani MJ et al., [23]	12	17	18	23	7.6%	0.67 [0.16, 2.81]	
Papasotiriou M et al [25]	26	47	36	52	25.8%	0.55 [0.24, 1.25]	+
Rao NN et al., [26]	18	27	19	27	10.7%	0.84 [0.27, 2.66]	
Total (95% CI)		238		257	100.0%	0.84 [0.57, 1.22]	•
Total events	145		171				
Heterogeneity: Chi <sup>2</sup> = 4.69	. df = 8 (p	= 0.79)	; l <sup>2</sup> = 0%				
Test for overall effect: Z =	0.93 (p=0	0.35)					0.01 0.1 1 10 10 Closed AVF Persistent AV

[Table/Fig-4]: Comparison of gender (Male) [16-19, 21-23, 25, 26].

There was a difference in Left Ventricular (LV) end diastolic diameter (mm) within the closed (M.D=2.48; p<0.001; 95% C.I=1.52 to 3.44) AVF group. In a persistent AVF group of patients, there was no difference (M.D=-0.18; p=0.86; 95% C.I=-2.23 to 1.86) in LV End Diastolic Diameter (LVEDD). The pooled estimate of LVEDD differed (M.D=2.0; p=0.02; 95% C.I=1.13 to 2.86) from baseline (pre) to atleast three months of postsurgery. It indicates that Left Ventricular end diastolic diameter was one of the determinants for AVF among HOHF patients [Table/Fig-5].

	Pre		Pos			Mean Difference		Mea	an Differen	се	
Study or Subgroup	Mean SD	Total	Mean SI	Total	Weight	IV, Fixed, 95% CI		IV,	Fixed, 95%	CI	
Within closed AVF group											
Duijnhoven EC et al, [15]	51.5±5.8	20	46.2±6.6	20	5.1%	5.30 [1.45, 9.15]			-		
Unger P et al., [16]	29.9±2.2	17	27.4±2.1	17	36.1%	2.50 [1.05, 3.95]					
Unger P et al., [18]	29.5±3.4	17	26.9±2.9	17	16.7%	2.60 [0.48, 4.72]					
Unger P et al., [20]	29.5±3.4	16	27.5±2.5	16	17.6%	2.00 [-0.07, 4.07]					
Głowiński J et al., [22] Subtotal (95% CI)	46.4±3.8	9 79	45.3±3.6	9 79	6.4% 81.9%	1.10 [-2.32, 4.52] 2.48 [1.52, 3.44]			Ţ		
Heterogeneity: Chi2 = 2.91,	df = 4 (P = 0	).57); l²	= 0%								
Test for overall effect: Z = 5	5.06 (P < 0.00	0001)									
Within persistent AVF gro	up										
Unger P et al., [16]	29±3.3	6	29.2±3.6	6	4.9%	-0.20 [-4.11, 3.71]			+		
Unger P et al., [18]	29.5±3.4	8	29±3.2	8	7.2%	0.50 [-2.74, 3.74]			+		
Głowiński J et al., [22]	45.3±3.6	9	46.3±4.1	9	5.9%	-1.00 [-4.56, 2.56]			+		
Subtotal (95% CI)		23		23	18.1%	-0.18 [-2.23, 1.86]			1		
Heterogeneity: Chi <sup>2</sup> = 0.37, Test for overall effect: Z = 0			= 0%								
Total (95% CI)		102		102	100.0%	2.00 [1.13, 2.86]					
Heterogeneity: Chi <sup>2</sup> = 8.62,	df = 7 (p = 0)	).28): l <sup>2</sup>	= 19%				<u> </u>	-	_	+	
Test for overall effect: Z = 4							-100	-50	0	50	100
Test for subgroup difference			1(p = 0.02)	),   <sup>2</sup> = 81	1.3%		Pre				Post
[Table/Fig-5]: ( [15,16,18,20,22		ison	of the	left ve	entricu	ılar end diast	olic c	liame	ter (mn	n)	
[[10,10,10,20,22	1.										

The Left Ventricular Mass Index (LVMI) within the closed AVF group from (M.D=11.93; p=0.02; 95% C.I=2.21 to 21.66) pre to post measurements exhibited a change. Among the patients with a persistent AVF, there was no change (M.D=1.19; p=0.80; 95% C.I=-8.06 to 10.44) in LVMI. Also, there was no difference (M.D=6.29; p=0.07; 95% C.I=-0.41 to 12.99) in the pooled estimate of LVMI [Table/Fig-6].

For cardiac index, there was no difference within the closed (M.D=0.83; p<0.001; 95% C.I=0.64 to 1.02) AVF group as well

Journal of Clinical and Diagnostic Research. 2022 Sep, Vol-16(9): OE07-OE12

		Pre		P	ost			Mean Difference		Me	an Diffe	rence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV,	Fixed, 9	5% CI	
Within closed AVF group	)												
Duijnhoven EC et al, [15]	135	134.1	20	119.8±	23.2	20	13.8%	15.20 [-2.88, 33.28]				_	
Unger P et al., [16]	141	± 37	17	132	± 39	17	6.9%	9.00 [-16.55, 34.55]			+		
Unger P et al., [18]	139.4	± 43	17	127 ±	± 45	17	5.1%	12.40 [-17.19, 41.99]			-		
Unger P et al., [20]	148	± 44	16	137 ±	± 40	16	5.3%	11.00 [-18.14, 40.14]			-		
Głowiński J et al., [22]	118.5	£26.3	9	113.1±	21.6	9	9.1%	5.40 [-16.83, 27.63]			-+-	_	
Dundon BK et al., [24]	166	± 56	18	149 1	51	18	3.7%	17.00 [-17.99, 51.99]			+		
Rao NN et al., [26] Subtotal (95% CI)	166	± 56	18 115	149 1	51	18 115	3.7% 47.5%	17.00 [-17.99, 51.99] 11.93 [2.21, 21.66]				•	
Heterogeneity: Chi <sup>2</sup> = 0.67	df = 6 (l)	P = 1 (	00):  2 =	0%							1		
Test for overall effect: Z = 2				0.0									
Within persistent AVF gr	oup												
Unger P et al., [16]	153	± 63	6	151 ±	59	6	0.9%	2.00 [-67.06, 71.06]			-		_
Unger P et al., [18]	139.4	± 43	8	114 1	± 19	8	4.2%	25.40 [-7.18, 57.98]			+		
Głowiński J et al., [22]	116:	± 225	9	115.6±	18.5	9	0.2%	0.40 [-147.09, 147.89]	•				$\rightarrow$
Rao NN et al., [26] Subtotal (95% CI)	76.1±	18.7	27 50	77.1±	17.9	27 50	47.1% 52.5%	-1.00 [-10.76, 8.76] 1.19 [-8.06, 10.44]			*		
Heterogeneity: Chi <sup>2</sup> = 2.32 Test for overall effect: Z = 0				0%							Ī		
Total (95% CI)			165			165	100.0%	6.29 [-0.41, 12.99]			•		
Heterogeneity: Chi <sup>2</sup> = 5.45	. df = 10	(p = 0	.86); l <sup>2</sup>	= 0%					H	-	_	-	
Test for overall effect: Z =	1.84 ( p=	0.07)							-100	-50	0	50	100
Test for subgroup difference	ces: Chi2	= 2.46	6, df = 1	(p=0.1	12), I <sup>2</sup>	= 59.4	%		Pre				Post
[Table/Fig-6]: [15,16,18,20,22	Com	ipar	ison					ular mass inde:	< (g∕r	m²)			

as a persistent AVF group (M.D=0.04; p=0.79; 95% C.I=-0.28 to 0.36). The combined estimate of cardiac index changed (M.D=0.63; p<0.001; 95% C.I=0.46 to 0.79) from baseline (pre) to atleast three months of postsurgery. It indicates that cardiac index was a determinant for AVF [Table/Fig-7].

	F	Pre		F	Post			Mean Difference		Mea	n Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, F	ixed, 95	% CI	
Within closed AVF gro	up												
Unger P et al., [16]	4.03±	0.66	17	3.2±	0.62	17	14.4%	0.83 [0.40, 1.26]			- <b>F</b>		
Unger P et al., [18]	3.86±	0.78	17	3.04	0.55	17	12.9%	0.82 [0.37, 1.27]			+ -		
Unger P et al., [20]	3.53±	0.83	16	2.62	0.68	16	9.6%	0.91 [0.38, 1.44]			- + -		
Dundon BK et al., [24]	9.6 ±	2.9	18	8.1	± 2.3	18	0.9%	1.50 [-0.21, 3.21]			ł		
Rao NN et al., [26]	3.3 ±	0.6	27	2.5	± 0.4	27	36.0%	0.80 [0.53, 1.07]			•		
Subtotal (95% CI)			95			95	73.9%	0.83 [0.64, 1.02]					
Heterogeneity: Chi <sup>2</sup> = 0.													
Test for overall effect: Z	= 8.59 (F	< 0.0	00001)										
Within Pesistent AVF	group												
Unger P et al., [18]	3.86±	0.78	8	3.58±	0.87	8	4.1%	0.28 [-0.53, 1.09]			- + -		
Rao NN et al., [26]	3.4 ±	0.6	27	3.4 :	± 0.7	27	22.0%	0.00 [-0.35, 0.35]			•		
Subtotal (95% CI)			35			35	26.1%	0.04 [-0.28, 0.36]					
Heterogeneity: Chi <sup>2</sup> = 0.	39. df = 1	(P=	0.53);	<sup>2</sup> = 0%									
Test for overall effect: Z	= 0.27 (F	= 0.7	'9)										
Total (95% CI)			130			130	100.0%	0.63 [0.46, 0.79]					
Heterogeneity: Chi <sup>2</sup> = 18	341 df =	6(p=	0.005	i): $l^2 = 62$	7%				<b>—</b>	-	_	-	
Test for overall effect: Z									-100	-50	0	50	1
Test for subgroup differe					< 0.00	01) 12	= 94 2%		Pre				Po
	511003. OI			1 - 110	- 0.00	01/.1	- 04.2.70						

Among the patients with a closed AVF, there was no difference (M.D=1.08; p=0.47; 95% C.I=-1.86 to 4.02) in the ejection fraction (%) and for the persistent AVF group, there was a difference (M.D=-3.47; p=0.03; 95% C.I=-6.55 to-0.38) in Ejection Fraction (EF) from baseline (pre) to atleast three months of postsurgery. There was no difference (M.D=-1.08; p=0.32; 95% C.I=-3.21 to 1.04) in the overall estimates of EF and hence it was not associated with HOHF-AVF [Table/Fig-8].

	Pre		Post			Mean Difference		Mean D	ifference	
Study or Subgroup	Mean SD	Total	Mean SD	Total	Weight	IV, Fixed, 95% CI		IV, Fixe	d, 95% CI	
Within closed AVF grou	qr									
Unger P et al., [16]	70 ± 10	17	69 ± 10	17	10.0%	1.00 [-5.72, 7.72]			+	
Głowiński J et al., [22] Subtotal (95% CI)	62.3 ± 4	9 26	61.2 ± 3	9 26	42.4% 52.4%	1.10 [-2.17, 4.37] 1.08 [-1.86, 4.02]			•	
Heterogeneity: Chi <sup>2</sup> = 0.0 Test for overall effect: Z =			; I² = 0%							
Within persistent AVF	group									
Unger P et al., [16]	61 ± 6	6	65 ± 10	6	5.2%	-4.00 [-13.33, 5.33]		_	+	
Głowiński J et al., [22] Subtotal (95% CI)	60 ± 3	9 15	63.4 ± 4	9 15		-3.40 [-6.67, -0.13] -3.47 [-6.55, -0.38]			)	
Heterogeneity: Chi <sup>2</sup> = 0.0 Test for overall effect: Z =			; I² = 0%							
Total (95% CI)		41		41	100.0%	-1.08 [-3.21, 1.04]			•	
Heterogeneity: Chi <sup>2</sup> = 4.3 Test for overall effect: Z		.32)		04)   <sup>2</sup> =	= 77 2%		-100 Pre	-50	0 50	100 Post

The posterior wall thickness (mm) within closed (M.D=-0.10; p=0.81; 95% C.I=-0.94 to 0.74) AVF group as well as a persistent AVF group (M.D=-0.20; p=0.58; 95% C.I=-0.91 to 0.51) was consistent. There was no difference (M.D=-0.16; p=0.86; 95% C.I=-0.70 to 0.38) in the pooled estimate of Posterior Wall Thickness (PWT) during the AVF procedures. Hence PWT was not associated with the AVF [Table/Fig-9].

Interventricular septum (mm) within the closed (M.D=0.50; p=0.32; 95% C.I=-0.48 to 1.48) AVF group as well as persistent AVF group (M.D=-0.10; p=0.80; 95% C.I=-0.89 to 0.69) exhibited no change. There was no difference (M.D=0.14; p=0.35; 95% C.I=-0.48 to 0.75) in the combined estimate of Interventricular Septum (IVS) during AVFs and hence IVS was not associated with the AVFs among HOHF patients [Table/Fig-10].

Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C		IV,	Fixed, 959	% CI	
Within closed AVF gro	up												
Głowiński J et al., [22]	11	±0.9	9	10.5	±1.2	9	39.2%	0.50 [-0.48, 1.48]					
Subtotal (95% CI)			9			9	39.2%	0.50 [-0.48, 1.48]					
Heterogeneity: Not appl	icable												
Test for overall effect: Z	= 1.00	(p=(	).32)										
Within persistent AVF	group												
Głowiński J et al., [22]	11	±0.8	9	11.1	±0.9	9	60.8%	-0.10 [-0.89, 0.69]					
Subtotal (95% CI)			9			9	60.8%	-0.10 [-0.89, 0.69]					
Heterogeneity: Not appl	icable												
Test for overall effect: Z	= 0.25	(p=(	0.80)										
Total (95% CI)			18			18	100.0%	0.14 [-0.48, 0.75]					
Heterogeneity: Chi <sup>2</sup> = 0.	.88. df =	1(P	= 0.35)	$ ^{2} = 0$	6				H	+	_	+	
Test for overall effect: Z	= 0.43	(p=(	0.67)						-100	-50	0	50	100
Test for subgroup different	ences: C	Chi <sup>2</sup> =	0.88, 0	If = 1 (F	= 0.3	35), l² =	0%		Pre				Post
[Table/Fig-10]	: Cc	mp	ariso	on of	the	Inte	r vent	ricular septur	n [22	].			

In this study, an AVF with flow rate >680 mL/minutes was considered as high flow fistula and <680 mL/minutes as low flow. This stratification of flow rate was reported in one study among the nine studies included in meta-analysis. There was a difference (M.D=-18.90; p<0.001; 95% C.I=-22.84 to-14.96) in left ventricular systolic diameter according to the flow rate and hence the LV systolic diameter was associated with AVF flow. However, there was no association between LV diastolic diameter (M.D=0.40; p=0.86; 95% C.I=-3.98 to 4.78), LV mass index (M.D=15.70; p=0.07; 95% C.I=-1.55 to 32.95) and the AVF flow [Table/Fig-11].

	AVF Flow (H	igh)	AVF Flow (L	.ow)		Mean Difference	Mean Diff	erence
Study or Subgroup	Mean SD	Total	Mean SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixed,	95% CI
VDED								
Cridlig J et al., [19] Subtotal (95% CI)	52.5 ± 7.6	19 19	52.1 ± 6.1	19 19	43.4% 43.4%	0.40 [-3.98, 4.78] 0.40 [-3.98, 4.78]		
leterogeneity: Not appli	icable							
Test for overall effect: Z		36)						
Cridlig J et al., [19] Subtotal (95% CI)	34.1 ± 6.9	19 19	53 ± 5.4	19 19		-18.90 [-22.84, -14.96] -18.90 [-22.84, -14.96]	•	
Heterogeneity: Not appli Fest for overall effect: Z _VMI		00001)						
Cridlig J et al., [19] Subtotal (95% CI)	142.6±30.02	19 19	126.9 ± 23.9	19 19	2.8% 2.8%	15.70 [-1.55, 32.95] 15.70 [-1.55, 32.95]		•
Heterogeneity: Not appli Fest for overall effect: Z		07)					-100 -50 0 AVF Flow (High)	50 100 AVF Flow (Low

according to AVF flow [19].

According to AVF flow, there was a difference (M.D=0.50; p=0.007; 95% C.I=0.14 to 0.86) in cardiac index and tricuspid annular plane systolic excursion (M.D=3.90; p=0.03; 95% C.I=0.30 to 7.50). Ejection fraction (M.D=3.32; p=0.92; 95% C.I=-0.44 to 7.08), E/A ratio (M.D=0.0; p=1.00; 95% C.I=-0.13 to 0.13), left atrial diameter (M.D=2.10; p=0.24; 95% C.I=-1.37 to 5.57), pulmonary arterial pressure (M.D=2.20; p=0.17; 95% C.I=-0.92 to 5.32), AVF Area (M.D=0.79; p=0.07; 95% C.I=-1.40 to 2.98), time deceleration of the "E" wave (M.D=1.80; p=0.90; 95% C.I=-25.67 to 29.27) were consistent with respect to AVF flow [Table/Fig-12-17].

	AVF	Flow (	High)	AVF FI	low (L	.ow)		Mean Difference	Mean Dif	ference
Study or Subgroup	Mean	SE	) Total	Mean	SD	Total	Weight	IV, Fixed, 95% 0	IV, Fixed	, 95% CI
Teicholz										
Cridlig J et al., [19] Subtotal (95% CI)	63.8	± 8.3	3 19 19	60.3 ±	7.5	19 19	55.9% 55.9%	3.50 [-1.53, 8.53] 3.50 [-1.53, 8.53]		•
Heterogeneity: Not app Test for overall effect: 2 Four cavities		(p=(	).17)							
Cridlig J et al., [19] Subtotal (95% CI)	59.9	± 7.9	) 19 19	56.8 ±	9.8	19 19	44.1% 44.1%	3.10 [-2.56, 8.76] 3.10 [-2.56, 8.76]		
Heterogeneity: Not app Test for overall effect: 2		(p=(	).28)							
Total (95% CI)			38			38	100.0%	3.32 [-0.44, 7.08]		•
Heterogeneity: Chi <sup>2</sup> = 0 Test for overall effect: 2 Test for subgroup differ	Z = 1.73	(p=(	0.08)		92) 1	<sup>2</sup> = 0%		-	-100 -50 0 AVF Flow (High)	50 100 AVF Fllow (Lov

Total (95% CI)			19			19	100.0%	0.50 [0.14, 0.86]	
Heterogeneity: Not ap Test for overall effect:		p = 0.	007)						-100 -50 0 50 100 AVF Flow (High) AVF Fllow (Low)
[Table/Fig-1	<b>3]:</b> Co	omp	ariso	n of c	ardi	ac in	dex (l/	′min/m²) acc	ording to AVF flow[19].
[Table/Fig-1	3]: Co			N OF C			dex (l/	(min/m <sup>2</sup> ) acc Mean Difference	ording to AVF flow[19].
[Table/Fig-1			ligh)	AVF FI		_ow)	dex (l/ Weight	Mean Difference	Mean Difference
	AVF F Mean	low (H	ligh)	AVF FI Mean	low (L SD	Low) Total	Weight	Mean Difference IV, Fixed, 95% (	Mean Difference CI IV, Fixed, 95% CI
Study or Subgroup	AVF F Mean	low (H SD	ligh) Total	AVF FI Mean	low (L SD	Low) Total	Weight	Mean Difference IV, Fixed, 95% ( 0.00 [-0.13, 0.13	Mean Difference CI IV, Fixed, 95% CI
Study or Subgroup Cridlig J et al., [19]	AVF F <u>Mean</u> 1.1 ±	low (H SD 0.2	ligh) <u>Total</u> 19 19	AVF FI Mean	low (L SD	-ow) Total 19	Weight 100.0%	Mean Difference IV, Fixed, 95% ( 0.00 [-0.13, 0.13	Mean Difference CI IV, Fixed, 95% CI

	AVF I	Flow (I	ligh)	AVF F	low (L	.ow)		Mean Difference	Mean Diff	erence
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixed,	95% CI
APSE (mm)										
Cridlig J et al., [19] Subtotal (95% CI)	27.6	± 5.4	19 19	23.7 ±	5.9	19 19	29.4% 29.4%	3.90 [0.30, 7.50] 3.90 [0.30, 7.50]		
leterogeneity: Not appl	licable								ſ	
est for overall effect: Z AD (mm)		(p=0	.03)							
Cridlig J et al., [19]	42.1	± 5.8	19	40 ±	5.1	19	31.5%	2.10 [-1.37, 5.57]	•	
Subtotal (95% CI)			19			19	31.5%	2.10 [-1.37, 5.57]	•	
eterogeneity: Not appl	licable									
est for overall effect: Z	= 1.19	(p = 0)	.24)							
PAPs (mmHg)										
Cridlig J et al., [19]	29.6	± 5.2	19	27.4 ±	4.6	19	39.0%	2.20 [-0.92, 5.32]	· •	
Subtotal (95% CI)			19			19	39.0%	2.20 [-0.92, 5.32]	•	
eterogeneity: Not appl	licable								ŀ	
est for overall effect: Z	= 1.38	(p = 0)	.17)						-100 -50 0	50 100
		<b>(</b> .	,						AVF Flow (High)	AVF Flow (Low

left atrial diameter (LAD), pulmonary arterial pressure (PAPs) according to AVF flow [19].

	AVE	AVF Flow (High)			AVF Fllow (Low)			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% (	CI IV, Fixed, 95% CI
Left Atria									
Cridlig J et al., [19] Subtotal (95% CI)	17.2	± 4.5	19 19	18.4	± 5.1	19 19		-1.20 [-4.26, 1.86 -1.20 [-4.26, 1.86]	
Heterogeneity: Not ap Test for overall effect:		(p=0.	44)						
Right Atria			,						
Cridlig J et al., [19] Subtotal (95% CI)	18.8	± 5.1	19 19	15.9	± 4.8	19 19	48.5% 48.5%		
Heterogeneity: Not ap Test for overall effect:		(p = 0.	07)						
Total (95% CI)			38			38	100.0%	0.79 [-1.40, 2.98]	ı •
Test for overall effect: Test for subgroup diffe				= 1 (P=	0.07),	l² = 70.2	2%		AVF Flow (High) AVF Fllow (Lov
[Table/Fig-1	6]: C	omp	ariso	n of .	AVF	Area	(cm²)a	according tc	AVF flow[19].
[Table/Fig-1								0	
		low (Hi	gh)		ilow (L	ow)		According to Mean Difference IV. Fixed, 95% (	Mean Difference
Study or Subgroup	AVF F	low (Hi SD	gh) Total	AVF F	ilow (L SD	ow) Total	Weight	Mean Difference	Mean Difference Cl IV, Fixed, 95% Cl
Study or Subgroup Cridlig J et al., [19]	AVF F Mean	low (Hi SD	gh) Total	AVF F Mean	ilow (L SD	ow) <u>Total</u> 19	Weight 100.0%	Mean Difference IV, Fixed, 95% (	Mean Difference Cl IV, Fixed, 95% Cl
Study or Subgroup Cridlig J et al., [19] Total (95% CI)	AVF F Mean 203.6 ±	low (Hi SD	gh) <u>Total</u> 19	AVF F Mean	ilow (L SD	ow) <u>Total</u> 19	Weight 100.0%	Mean Difference IV, Fixed, 95% ( 1.80 [-25.67, 29.27	Mean Difference
[Table/Fig-10 Study or Subgroup Cridig J et al., [19] Fotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2	AVF F Mean 203.6 ±	low (Hi SD 39.5	gh) <u>Total</u> 19 19	AVF F Mean	ilow (L SD	ow) <u>Total</u> 19	Weight 100.0%	Mean Difference IV, Fixed, 95% ( 1.80 [-25.67, 29.27] 1.80 [-25.67, 29.27]	Mean Difference Cl IV, Fixed, 95% Cl

# DISCUSSION

Left Ventricular (LV) hypertrophy or dilatation and systolic dysfunction were common among chronic kidney disease patients [30]. AVF is a surgically created form for the chronic vascular access in haemodialysis therapy. Venous stenosis and thrombosis are associated with the failure of AVF and remains a major determinant for hospitalisation and morbidity among the haemodialysis cases [31]. Ligation of the AVF followed by renal transplantation may result the decrease in LV mass, LV and left atrial volumes, and hence there was a higher chance of reversibility of the cardiac adaptive remodeling [32]. The structural cardiac changes associated with AVF are adaptive and reversible.

In this study, the left ventricular end diastolic diameter from baseline to atleast three months of postsurgery (follow-up) differed and hence LVEDD (mm) was associated with HOHF-AVF. The combined estimate of cardiac index differed from baseline to follow-up and it indicates that cardiac index was a determinant for a HOHF-AVF. There was no difference in the overall estimates of ejection fraction (EF), PWT, and IVS. Hence, the EF (%), PWT, and IVS were not associated with the HOHF-AVF. Upper arm AVFs (flows >2000 mL/min) were associated with an increased risk of HOHF and lower peripheral resistance [33-35]. High flow within the AVF may underlie the onset of HOHF and it was characterised by a cardiac index more than 3.9 l/min/m<sup>2</sup> [27,35].

In this study, the LV systolic diameter, cardiac index and tricuspid annular plane systolic excursion were associated with AVF flow. There was no association between LV diastolic diameter, LV mass index, Ejection fraction, E/A ratio, left atrial diameter, pulmonary arterial pressure, AVF Area, and time deceleration of the "E" wave; and the AVF flow. The venous return (excessive) to the heart by high-flow AVF can provide the myocardial protection through cardiopulmonary bypass. Aortic Stenosis (AS), aortic regurgitation, mitral regurgitation and tricuspid regurgitation were common among patients on haemodialysis with a prevalence of 39-43%. However, the AVF-associated volume load of patients with valvular heart disease was limited to patients with AS [36,37].

Increased oxygen demand, structure of artery bypass graft, and CABG were the contributing factors for an AVF. Even though AVF closure is not routinely performed in patients with stable renal allograft function, it is associated with cardiac functions and survival of allograft. However, spontaneous or planned AVF closure may not yield favourable results on echocardiographic indices [37].

#### Limitation(s)

There is a paucity of evidence about the body mass index or obesity, signs of HOHF-AVF, and duration of AVF use. Haemodynamic stabilisers such as dietary restriction (salt and water), diuretics and vasoconstrictor adrenergic drug use have been demonstrated an effect on the creation or closure of AVF and its follow-up. However, the present findings suggest that there is a need for more clinical studies on the treatment regimens of HOHF.

# CONCLUSION(S)

Left ventricular end diastolic diameter and cardiac index were found to be the major determinants for a HOHF-AVF. The left ventricular mass index, ejection fraction, posterior wall thickness, interventricular septum were not associated with HOHF-AVF. Left ventricular systolic diameter, cardiac index and tricuspid annular plane systolic excursion were the determinants of AVF flow. The ejection fraction, left atrial diameter, "E/A" ratio, pulmonary arterial pressure, AVF area, time deceleration of the "E" wave were consistent with respect to AVF flow.

# REFERENCES

- Lok CE. Fistula first initiative: Advantages and pitfalls. Clin J Am Soc Nephrol. 2007;2:1043-53. Doi: https://doi.org/10.2215/CJN.01080307. PMID: 17702726.
- [2] Chang RS, Hu JR, Beckman JA, Forbes RC, Shawar SH, Concepcion BP. High output heart failure associated with arteriovenous fistula in the setting of kidney transplantation. Kidney Int Rep. 2020;6(2):544-51. Doi: https://doi.org/10.1016/j. ekir.2020.11.002. PMID: 33615082.
- [3] Wasse H, Singapuri MS. High-output heart failure: how to define it, when to treat it, and how to treat it. Semin Nephrol. 2012;32(6):551-57. Doi: https://doi. org/10.1016/j.semnephrol.2012.10.006. PMID: 23217335.
- [4] Tellioglu G, Berber I, Kilicoglu G, Seymen P, Kara M, Titiz I. Doppler ultrasonography-guided surgery for high flow hemodialysis vascular access: Preliminary results. Transplant Proc. 2008;40(1):87-89. Doi: https://doi. org/10.1016/j.transproceed.2007.11.059. PMID: 18261553.
- [5] Pasklinsky G, Meisner RJ, Labropoulos N, Leon L, Gasparis AP, Landau D, et al. Management of true aneurysms of hemodialysis access fistulas. J Vasc Surg. 2011; 53(5):1291-97. Doi: https://doi.org/10.1016/j.jvs.2010.11.100. PMID: 21276676.
- [6] Stoumpos S, Mark PB. Should we ligate arteriovenous fistulas in asymptomatic patients after kidney transplantation? Circulation. 2019;139(25):2819-21. Doi: https://doi.org/10.1161/CIRCULATIONAHA.119.040361. PMID: 31206325.
- Pascual J, Martins J, Bouarich H, Galeano C, Barrios V, Marcen R, et al. Sudden death after arteriovenous fistula ligation in a renal transplant patient. Ann Vasc Surg. 2008;22(1):134-35. Doi: https://doi.org/10.1016/j.avsg.2007.07.031. PMID: 17993256.
- [8] Bonfante GM, Gomes IC, Andrade EI, Lima EM, Acurcio FA, Cherchiglia ML. Duration of temporary catheter use for hemodialysis: An observational, prospective evaluation of renal units in Brazil. BMC Nephrol. 2011;12:63-70. Doi: https://doi.org/10.1186/1471-2369-12-63. PMID: 22093280.
- [9] Valerianova A, Malik J, Janeckova J, Kovarova L, Tuka V, Trachta P, et al. Reduction of arteriovenous access blood flow leads to biventricular unloading in haemodialysis patients. Int J Cardiol. 2021;334:148-53. Doi: https://doi. org/10.1016/j.ijcard.2021.04.027. PMID: 33895210.

- [10] Laranjinha I, Matias P, Azevedo A, Navarro D, Ferreira C, Amaral T, et al. Are high flows arteriovenous accesses associated with worsehaemodialysis? Braz J Nephrol. 2018;40(2):136-42. Doi: https://doi.org/10.1590/2175-8239-jbn-3875. PMID: 29927460.
- [11] Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. Available from www.handbook. cochrane.org. Accessed date: 20/8/2021.
- [12] Joanna Briggs Institute Critical appraisal tools for use JBI systematic reviewers. Joanna Briggs Institute. 2017. The University of Adelaide South Australia 5005. Accessed date: 20/8/2021. Accessed date: 24/8/2021.
- [13] Julian PT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in Meta analysis. BMJ. 2003;327:557-60. Doi: https://doi.org/10.1136/ bmj.327.7414.557. PMID: 12958120.
- [14] RevMan 5 download RevMan web page. www.cc-ims.net/RevMan. Accessed date: 17/9/2021.
- [15] Van Duijnhoven EC, Cheriex EC, Tordoir JH, Kooman JP, Van Hooff JP. Effects of closure of the arteriovenous fistula on left ventricular dimensions in renal transplant patients. Nephrol Dial Transplant. 2001;16(2):368-72. Doi: https://doi. org/10.1093/ndt/16.2.368. PMID: 11158414.
- [16] Unger P, Wissing KM, De Pauw L, Neubauer J, Van De Borne P. Reduction of left ventricular diameter and mass after surgical arteriovenous fistula closure in renal transplant recipients. Transplantation. 2002;74(1):73-79. Doi: https://doi. org/10.1097/00007890-200207150-00013. PMID: 12134102.
- [17] Sheashaa H, Hassan N, Osman Y, Sabry A, Sobh M. Effect of spontaneous closure of arteriovenous fistula access on cardiac structure and function in renal transplant patients. Am J Nephrol. 2004;24(4):432-37. Doi: https://doi. org/10.1159/000080187. PMID: 15308876.
- [18] Unger P, Velez-Roa S, Wissing KM, Hoang AD, Van De Borne P. Regression of left ventricular hypertrophy after arteriovenous fistula closure in renal transplant recipients: A long-term follow-up. Am J Transplant. 2004;4(12):2038-44. Doi: https://doi.org/10.1046/j.1600-6143.2004.00608.x. PMID: 15575907.
- [19] Cridlig J, Selton-Suty C, Alla F, Chodek A, Pruna A, Kessier M, et al. Cardiac impact of the arteriovenous fistula after kidney transplantation: A casecontrolled, match-paired study. Transpl Int. 2008;21(10):948-54. Doi: https://doi. org/10.1111/j.1432-2277.2008.00707.x. PMID: 18537919.
- [20] Unger P, Xhaët O, Wissing KM, Najem B, Dehon P, Van De Borne P. Arteriovenous fistula closure after renal transplantation: A prospective study with 24-hour ambulatory blood pressure monitoring. Transplantation. 2009;85(3):482-85. Doi: https://doi.org/10.1097/TP.0b013e318160f163. PMID: 18301341.
- [21] Gorgulu N, Caliskan Y, Yelken B, Akturk F, Turkmen A. Effects of arteriovenous fistula on clinical, laboratory and echocardiographic findings in renal allograft recipients. Int J Artif Organs. 2011;34(10):1024-30. Doi: https://doi.org/10.5301/ ijao.5000005. PMID: 22161285.
- [22] Głowiński J, Małyszko J, Głowińska I, Myśliwiec M. To close or not to close: Fistula ligation and cardiac function in kidney allograft recipients. Pol Arch Med Wewn. 2012;122(7-8):348-52. Doi: https://doi.org/10.20452/pamw.1349. PMID: 22743626.
- [23] Soleimani MJ, Shahrokh H, Shadpour P, Shirani M, Arasteh S. Impact of dialysis access fistula on cardiac function after kidney transplantation. Iran J Kidney Dis. 2012;6(3):198-202.
- [24] Dundon BK, Torpey DK, Nelson AJ, Wong DT, Duncan RF, Meredith IT, et al. Beneficial cardiovascular remodeling following arteriovenous fistula ligation postrenal transplantation: A longitudinal magnetic resonance imaging study. Clin Transplant. 2014;28(8):916-25. Doi: https://doi.org/10.1111/ctr.12402. PMID: 24931318.
- [25] Papasotiriou M, Xanthopoulou I, Ntrinias T, Kalliakmani P, Koutsogiannis N, Davlouros P, et al. Impact of arteriovenous fistula on cardiac size and function in kidney transplant recipients: A retrospective evaluation of 5-year Echocardiographic outcome. Exp Clin Transplant. 2019;17(5):619-26. Doi: https://doi.org/10.6002/ect.2018.0331. PMID: 31180298.
- [26] Rao NN, Stokes MB, Rajwani A, Ullah S, Williams K, King D, et al. Effects of arteriovenous fistula ligation on cardiac structure and function in kidney transplant recipients. Circulation. 2019;139(25):2809-18. Doi: https://doi.org/10.1161/ CIRCULATIONAHA.118.038505. PMID: 31045455.
- [27] Malik J, Valerianova A, Tuka V, Trachta P, Bednarova V, Hruskova Z, et al. The effect of high-flow arteriovenous fistulas on systemic hemodynamics and brain oxygenation. ESC Heart Failure. 2021;8:2165-71. Doi: https://doi.org/10.1002/ ehf2.13305. PMID: 33755355.
- [28] Saleh MA, El Kilany WM, Keddis VW, El Said TW, Effect of high flow arteriovenous fistula on cardiac function in hemodialysis patients. Egypt Heart J. 2018:(70):337-41. Doi: https://doi.org/10.1016/j.ehj.2018.10.007. PMID: 30591752.
- [29] Salehi T, Montarello NJ, Juneja N, Stokes MB, Scherer DJ, Williams KF, et al. Long-term impact of arteriovenous fistula ligation on cardiac structure andfunction in kidney transplant recipients-A 5-year follow-up observational cohort study. Kidney. 2021;2:1141-47. Doi: https://doi.org/10.34067/KID.0000692021. PMID: 35368362.
- [30] De Simone G, Pasanisi F, Contaldo F. Link of non hemodynamic factors to hemodynamic determinants of left ventricular hypertrophy. Hypertension. 2001;38(1):13-18. Doi: https://doi.org/10.1161/01.HYP.38.1.13. PMID: 11463753.
- [31] Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: A cellular and molecular viewpoint. J Am Soc Nephrol. 2006;17(4):1112–27. Doi: https://doi.org/10.1681/ASN.2005050615. PMID: 16565259.
- [32] Lee SR, Thorn S, Guerrera N, Gonzalez L, Taniguchi R, Langford J, et al. Arteriovenous fistula-induced cardiac remodeling shows cardio protective features in mice. JVS. 2021;2:110-28. Doi: https://doi.org/10.1016/j.jvssci.2021.05.002.

#### Anusuya Premjithlal Bhaskaran et al., Pathophysiological Characteristics of HOHF-AVF

PMID: 34423320.

- [33] Basile C, Lomonte C. The complex relationship among arteriovenous access, heart, and circulation. Semin Dial. 2018;31:15-20. Doi: https://doi.org/10.1111/ sdi.12652. PMID: 28990213.
- [34] Yeh LM, Chiu SY, Lai PC. The impact of vascular access types on hemodialysis patient long-term survival. Sci Rep. 2019;9:10708. Doi: https://doi.org/10.1038/ s41598-019-47065-z. PMID: 31341241.
- [35] Moughal S, Bashir M, Mohammed I, Abdelhaliem A, Santawy HE, Khaffaf HA. High-output cardiac failure secondary to arteriovenous fistula: A wide-based literature review. Interv Cardiol. 2020;12(4):101-05.

#### PARTICULARS OF CONTRIBUTORS:

- 1. Department of Cardiovascular Surgery, Imperial College, London, United Kingdom.
- 2. Department of Cardiovascular Surgery, Imperial College, London, United Kingdom.
- 3. Department of Cardiothoracic Surgery, Imperial College, London, United Kingdom.

# NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR: Dr. Premjithlal Bhaskaran,

Department of Cardiothoracic Surgery, Imperial College, London, United Kingdom. E-mail: Ial@bhask.com

#### AUTHOR DECLARATION:

- Financial or Other Competing Interests: None
- Was informed consent obtained from the subjects involved in the study? NA
- · For any images presented appropriate consent has been obtained from the subjects. NA

- [36] Maresca B, Filice FB, Orlando S, Ciavarella GM, Scrivano J, Volpe M, et al. Early echocardiographic modifications after flow reduction by proximal radial artery ligation in patients with high output heart failure due to high flow forearm arteriovenous fistula. J Vasc Access. 2020;21(5):753-59. Doi: https://doi. org/10.1177/1129729820907249. PMID: 32103699.
- [37] Alkhouli M, Sandhu P, Boobes K, Hatahet K, Raza F, Boobes Y. Cardiac complications of arteriovenous fistulas in patients with end-stage renal disease. Nefrologia. 2015;35(3):234-45. Doi: https://doi.org/10.1016/j.nefro.2015.03.001. PMID: 26299166.

PLAGIARISM CHECKING METHODS: [Jain H et al.]

- Plagiarism X-checker: Dec 12, 2021
- Manual Googling: May 02, 2022
- iThenticate Software: Aug 10, 2022 (25%)

ETYMOLOGY: Author Origin

Date of Submission: Dec 09, 2021 Date of Peer Review: Jan 29, 2022 Date of Acceptance: May 03, 2022 Date of Publishing: Sep 01, 2022